Edición/Edição: 1st Autores:Liman S. Torres Editorial:Nova Science ISBN: 9781600215728 Formato: Tapa Dura/Hardback Nº volumenes: 1 Páginas: 266 Año publicación/Ano de publicação: 2007 Disponibilidad/Disponibilidade: 15 días Precio/Preço
:181,44 €172,37 €(179,26€ iva incluído)
(Sea el primero en opinar
) ¿Vas a pedir más de 5 productos? Escríbenos, te enviaremos presupuesto ajustado, envíanos mail
One of the main causes of failure in the treatment of cancer is the development of drug resistance by the cancer cells. The design of cancer chemotherapy has become increasingly sophisticated, yet there is no cancer treatment that is 100 percent effective against disseminated cancer. Resistance to treatment with anticancer drugs results from a variety of factors including individual variations in patients and somatic cell genetic differences in tumours, even those from the same tissue of origin. Frequently resistance is intrinsic to the cancer, but as therapy becomes more and more effective, acquired resistance has also become common.The most common reason for acquisition of resistance to a broad range of anticancer drugs is expression of one or more energy-dependent transporters that detect and eject anticancer drugs from cells, but other mechanisms of resistance including insensitivity to drug-induced apoptosis and induction of drug-detoxifying mechanisms probably play an important role in acquired anticancer drug resistance. Studies on mechanisms of cancer drug resistance have yielded important information about how to circumvent this resistance to improve cancer chemotherapy and have implications for pharmacokinetics of many commonly used drugs. This book presents new and important research in this field.
Expert commentary : development of drug resistance by cancer cells : a new perspective by Amit Verma and Kapil Mehta 1 Ch. I New research communications on cancer drug resistance by Nicolas Tsavaris and Elias Skopelitis 7 Ch. II Resistance to apoptosis : a mechanism associated with the sensitivity of head and neck cancers to anti-cancer drug therapy by Han-Ching Liu and George G. Chen and Alexander C. Vlantis and C. Andrew van Hasselt 29 Ch. III Mitotic checkpoint and its role in chemodrug sensitivity in human cancer by Xianghong Wang and Hiu Wing Cheung and Yong-Chuan Wong 47 Ch. IV New research communications on cancer drug resistance, assessment of cancer drug resistance with nuclear medicine images by Seigo Kinnya 65 Ch. V Epithelial-mesenchymal transition (EMT) and its involvement in acquired endocrine resistance in breast cancer by S. Hiscox and A. Borley and R. I. Nicholson and P. Barrett-Lee 81 Ch. VI Molecular mechanisms of cisplatin resistance in prostate cancer cells by Takeo Nomura and Hiromitsu Mimata 95 Ch. VII Early resistance to induction chemotherapy assessed by residua] blasts in bone marrow and/or peripheral blood at day 8 is associated with unfavorable outcomes in adult acute lymphoblastic leukemia by Xavier Thomas and Francoise Huguet and Andre Delannoy and Tibor Kovacsovics and Veronique Lheritier and Jean-Paul Vernant and Herve Dombret 107 Ch. VIII Spontaneous canine melanoma derived spheroids display individual multicellular resistance patterns to suicide gene and chemotherapy by Natalia A. Altamirano and Armando L. Karara and Marcela S. Villaverde and Gabriel L. Fiszman and Gerardo C. Glikin and Liliana M. E. Finocchiaro 119 Ch. IX Drug resistance to rapamycin through elevated phospholipase D activity by David A. Foster 139 Ch. X Stromal fibroblasts as determinants of the efficacy of anticancer therapy by Daniel Lafkas and Erasmia Tsellou and Hippokratis Kiaris 147 Ch. XI Overcoming chemoresistance in ovarian cancers by ultrasound by Tinghe Yu and Chuanshan Xu and Yan Yang 157 Ch. XII Arsenic therapy of acute promyelocytic leukemia (APL) : speciation of arsenic metabolites in a treated APL by Yasuomi Fukai and Miyuki Hirata and Mayumi Ueno and Naoaki Ichikawa and Hikaru Kobayashi and Hiroshi Saitoh and Teruaki Sakurai and Kenji Kinoshita and Toshikazu Kaise and Shin Ohta 167 More...